Showing 6401-6410 of 9528 results for "".
- UW's Simpson Lab Awarded $590K to Study Hailey-Hailey Diseasehttps://practicaldermatology.com/news/uws-simpson-lab-awarded-590k-to-study-hailey-hailey-disease/2462172/The Simpson Lab at the University of Washington has been awarded a three-year $590K grant by the LEO Foundation for ongoing research in Hailey-Hailey disease (HHD). Funding from this award will support Simpson Lab personnel and provide supplies for research aimed at investigating how mu
- DermWire’s AD Pipeline Watch: TDM 180935 Performs Well in Phase 1 Studyhttps://practicaldermatology.com/news/dermwires-ad-pipeline-watch-tdm-180935-performs-well-in-phase-1-study/2462168/Technoderma Medicines, Inc. has completed a Phase 1 clinical trial of TDM-180935 topical ointment for Atopic Dermatitis (AD). TDM 180935 is a small molecule drug candidate that functions as a potent JAK1/Tyk2 small molecule inhibitor. Preclinical assessment of TDM-180935 has demon
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid
- Can a New Bacteriocin Thwart Antibiotic Resistance?https://practicaldermatology.com/news/can-a-new-bacteriocin-thwart-antibiotic-resistance/2462150/A new bacteriocin in a very common skin bacterium may inhibit the growth of antibiotic-resistant bacteria, new research suggests. The research group for child and youth health at UiT The Arctic University of Norway has studied bacter
- Melanoma and Lung Cancer Drug May Also Treat Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/melanoma-and-lung-cancer-drug-may-also-treat-cutaneous-squamous-cell-carcinoma/2462149/Plixorafenib, a new drug developed for treating melanoma and lung cancer, may also stop the progression of cutaneous squamous cell carcinoma, new research suggests. Researchers out of the University of Turku, Finland, discovered that plixorafenib (also called PLX8394) simultaneously inh
- Take That, Melanoma! ATM Kinase Inhibitors May Stop Metastasishttps://practicaldermatology.com/news/take-that-melanona-atm-kinase-inhibitors-may-stop-metastasis/2462146/Ataxia telangiectasia mutated (ATM) kinase inhibition may target the metastatic capacity of melanoma cells, according to a research team led by Wolfgang Weninger and Shweta Tikoo from MedUni Vienna's Department of Dermatology. The results of the study, which appe
- AI In Action: Almirall, Absci AI Drug Discovery Partner to Rapidly Develop New treatments for Skin Diseaseshttps://practicaldermatology.com/news/ai-in-action-almirall-absci-ai-drug-discovery-partner-to-rapidly-develop-new-treatments-for-skin-diseases/2462135/Almirall S.A. and Absci Corporation, a generative artificial intelligence (AI) drug creation company, are teaming up to develop and commercialize AI-designed therapeutics to treat dermatological diseases. The partnership combines Absci’s Integrated Drug C
- FDA Accepts sBLA for Interchangeability Designation for Hadlima, a Humira Biosimilarhttps://practicaldermatology.com/news/fda-accepts-sbla-for-interchangeability-designation-for-hadlima-a-biosimilar-to-humira/2462131/The U.S. Food and Drug Administration (FDA) has accepted the Supplemental Biologics License Application (sBLA) for the interchangeability designation or Hadlima (adalimumab-bwwd) injection 40 mg/0.4 mL, a biosimilar to Humira(adalimumab). Once a biosimilar product is designated as an in
- ACAAI News: 72% of AD Patients Report Poor Mental Health for 1-10 Days in the Past Monthhttps://practicaldermatology.com/news/acaai-news-72-of-ad-patients-report-poor-mental-health-for-1-10-days-in-the-past-month/2462129/Folks with atopic dermatitis (AD) are more likely to report poor mental health than their counterparts without the inflammatory skin condition, new research shows. The study, which was presented at the 2023 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientif
- Updated AAD Guidelines on AD in Adults Back Use of Biologics, JAK Inhibitorshttps://practicaldermatology.com/news/updated-aad-guidelines-on-ad-in-adults-back-use-of-biologics-jak-inhibitors/2462123/Updated American Academy of Dermatology (AAD) guidelines on systemic treatment of atopic dermatitis (AD) in adults strongly back the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib. “When the last guidelines were published in 2014, only no